Impact of GnRH antagonist pretreatment on oocyte yield after ovarian stimulation: A retrospective analysis

PLoS One. 2024 Oct 7;19(10):e0308666. doi: 10.1371/journal.pone.0308666. eCollection 2024.

Abstract

The study investigates whether a 3-day pretreatment course with a GnRH antagonist in the early follicular phase has an impact on the number of retrieved COCs in a GnRH antagonist stimulation protocol. This is a retrospective single center crossover study involving women who did not conceive after one GnRH antagonist stimulation cycle ("standard cycle") and proceeded with another GnRH antagonist stimulation cycle preceded by early administration of GnRH antagonist for 3 days ("pretreatment cycle") with fresh embryo transfer or frozen embryo transfer. 430 patients undergoing 860 cycles were included. The mean female age was 34.4 ± 4.8 years. Indications for fertility treatment included unexplained infertility (34.3%), male-factor infertility (33.3%), age (16.9%), PCOS (8.2%), tubal (4.7) and endometriosis (2.6%). All cycles were divided into two groups: group 1 (standard, 430 cycles) and group 2 (pretreatment, 430 cycles). The mean duration of stimulation was similar in both groups (10.3 vs 10.3 days, p = 0.28). The starting dose of gonadotropin (234.9 vs 196.8 IU, p<0.001), total amount of gonadotropin used (2419 vs 2020 IU, p<0.001), the total number of retrieved COCs (10 vs 7.8 p<0.001) and the number of mature oocytes (8 vs 5.8 p<0.001) were significantly higher in group 2 than in group 1. The Generalized estimating equation (GEE) regression analysis showed that the pretreatment strategy had a significant positive effect on the number of COCs (coefficient 2.4, p <0.001 after adjusting for known confounders (age, indication, stimulation dose, type, and duration of stimulation). In conclusion, A 3-day course of GnRH antagonist pretreatment increases the number of COCs obtained after ovarian stimulation.

MeSH terms

  • Adult
  • Cross-Over Studies
  • Embryo Transfer / methods
  • Female
  • Fertilization in Vitro / methods
  • Gonadotropin-Releasing Hormone* / antagonists & inhibitors
  • Hormone Antagonists / administration & dosage
  • Hormone Antagonists / pharmacology
  • Humans
  • Oocyte Retrieval / methods
  • Oocytes* / drug effects
  • Ovulation Induction* / methods
  • Pregnancy
  • Retrospective Studies

Substances

  • Gonadotropin-Releasing Hormone
  • Hormone Antagonists

Grants and funding

The study was supported by Merck Belgium, an affiliate of Merck KGaA, Darmstadt, Germany, in terms of payment of article publication charges. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors are fully responsible for the content of this manuscript, and the views and opinions described in the publication reflect solely those of the authors. The authors received no specific funding for this work, none of the authors received a salary from Merck KGaA.